Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Strontium chloride is a salt of strontium and chlorine that exists in both non-radioactive (SrCl2) and radioactive forms (notably Strontium-89 Chloride). The radioactive form (strontium-89 chloride) is used as a radiopharmaceutical agent for the relief of bone pain associated with skeletal metastases from cancers such as prostate and breast cancer. After intravenous injection, it behaves similarly to calcium by localizing in areas of active bone formation—especially metastatic lesions—where it emits beta radiation that helps reduce pain and may have tumoricidal effects. Non-radioactive formulations were previously used in toothpaste for dentin hypersensitivity but are now largely obsolete[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Strontium chloride.